Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $548.96, for a total value of $5,215,120.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,240,016.48. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $554.34 on Thursday. The firm’s fifty day moving average price is $557.51 and its two-hundred day moving average price is $529.07. The stock has a market cap of $23.53 billion, a PE ratio of 20.46, a PEG ratio of 1.85 and a beta of 0.58. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the company posted $6.63 earnings per share. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC grew its stake in shares of United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its stake in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.